Robust Growth Glaukos is expanding revenue with high single to mid double-digit growth, signaling ample budget and willingness to invest in portfolio expansion, which presents opportunities for new therapies, devices, or add-on services in ophthalmic care.

Retina Focus Recent exclusive licensing with RevOpsis for multiple retinal therapies and RO-104 indicates a strategic push in retinal diseases (nAMD, DME, DR, RVO), suggesting sales opportunities for related biologics, delivery platforms, and long-term collaboration in retina pipeline products.

Dropless Platform Glaukos highlights a robust pipeline of dropless platform technologies aimed at improving chronic eye disease care, presenting cross-sell potential for pharmacologic and device solutions that reduce patient injections and enhance adherence.

Key Market Access Exclusive rights for PRESERFLO MicroShunt in major markets and ongoing adoption with favorable real-world evidence create opportunities to bundle training, post-market surveillance, and regional expansion services for eye surgery devices.

Scale and Capex Large company with substantial revenue and a sizable market cap, plus global market presence, implies capacity for large-scale deployments, preferred vendor relationships, and multi-site implementation opportunities in hospitals, clinics, and distribution channels.